Navigator Medicines announced it raised $50 Million in an initial filing from an offering of $100 Million

Company

Location

About

Navigator Medicines is a biotech company leading the advancement of biologics for targeted immune regulation & restoration. Founded in 2024 as a subsidiary of Sera Medicines, the Company is committed to developing new therapies for patients living with complex, heterogeneous autoimmune diseases. NAV-240, their clinical-stage bispecific antibody, targets OX40L and TNFα to address critical inflammatory diseases. The company is focused on innovation that enhances patient care.